{"title":"卡维地洛在HFrEF患者中的实际应用与临床试验数据一致吗?在私人心脏病专家那里工作了21年","authors":"","doi":"10.36879/jcr.20.000130","DOIUrl":null,"url":null,"abstract":"Carvedilol has been approved for treatment of New York Heart Association (NYHA) Class I, II, III and IV patients and post-Myocardial\nInfarction (MI) patients, if the patient's Ejection Fraction (EF) is less than 40% because this third-generation beta-blocker demonstrated a\ndecrease in mortality. While clinical trials demonstrated the survival benefits of carvedilol, translating carvedilol's efficacy and usefulness in\nclinical practice requires understanding of its side effect profile and the importance of dosage and long-term monitoring.A database on use of\ncarvedilol in a private cardiologist's practice was begun in 1997 and concluded at the end of 2018.We report analysis of 642 patients with\nHFrEF. Initial EF's ranged between 8 and 47% with mean EF 32 ± 6%. The average age of the patient when started on carvedilol was 69 ± 7\nyears. Only 7 patients were changed to metoprolol succinate because of adverse side effects. After up-titration of carvedilol, the average resting\nheart rate was 61 ± 8 beats per minute. Two hundred and forty patients with HFrEF on carvedilol for greater than 5 years had a significant mean\nincrease in EF of 5.5 ± 8% (p < 0.05). Two hundred of the patients with HFrEF also had or developed type 2 diabetes and chronic kidney disease\nduring followup. Thirty-one percent of these patients with type 2 diabetes and chronic kidney disease lived longer than 10 years. Carvedilol\nremains a well-tolerated beta-blocker which demonstrates long-term benefits in a real-world setting.","PeriodicalId":15200,"journal":{"name":"Journal of Cardiology & Current Research","volume":"67 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2020-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Is Real World Use of Carvedilol in Patients with HFrEF Consistent with Clinical Trial Data? A 21-Year Experience in a Private Cardiologist's\",\"authors\":\"\",\"doi\":\"10.36879/jcr.20.000130\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Carvedilol has been approved for treatment of New York Heart Association (NYHA) Class I, II, III and IV patients and post-Myocardial\\nInfarction (MI) patients, if the patient's Ejection Fraction (EF) is less than 40% because this third-generation beta-blocker demonstrated a\\ndecrease in mortality. While clinical trials demonstrated the survival benefits of carvedilol, translating carvedilol's efficacy and usefulness in\\nclinical practice requires understanding of its side effect profile and the importance of dosage and long-term monitoring.A database on use of\\ncarvedilol in a private cardiologist's practice was begun in 1997 and concluded at the end of 2018.We report analysis of 642 patients with\\nHFrEF. Initial EF's ranged between 8 and 47% with mean EF 32 ± 6%. The average age of the patient when started on carvedilol was 69 ± 7\\nyears. Only 7 patients were changed to metoprolol succinate because of adverse side effects. After up-titration of carvedilol, the average resting\\nheart rate was 61 ± 8 beats per minute. Two hundred and forty patients with HFrEF on carvedilol for greater than 5 years had a significant mean\\nincrease in EF of 5.5 ± 8% (p < 0.05). Two hundred of the patients with HFrEF also had or developed type 2 diabetes and chronic kidney disease\\nduring followup. Thirty-one percent of these patients with type 2 diabetes and chronic kidney disease lived longer than 10 years. Carvedilol\\nremains a well-tolerated beta-blocker which demonstrates long-term benefits in a real-world setting.\",\"PeriodicalId\":15200,\"journal\":{\"name\":\"Journal of Cardiology & Current Research\",\"volume\":\"67 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-03-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Cardiology & Current Research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.36879/jcr.20.000130\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cardiology & Current Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.36879/jcr.20.000130","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Is Real World Use of Carvedilol in Patients with HFrEF Consistent with Clinical Trial Data? A 21-Year Experience in a Private Cardiologist's
Carvedilol has been approved for treatment of New York Heart Association (NYHA) Class I, II, III and IV patients and post-Myocardial
Infarction (MI) patients, if the patient's Ejection Fraction (EF) is less than 40% because this third-generation beta-blocker demonstrated a
decrease in mortality. While clinical trials demonstrated the survival benefits of carvedilol, translating carvedilol's efficacy and usefulness in
clinical practice requires understanding of its side effect profile and the importance of dosage and long-term monitoring.A database on use of
carvedilol in a private cardiologist's practice was begun in 1997 and concluded at the end of 2018.We report analysis of 642 patients with
HFrEF. Initial EF's ranged between 8 and 47% with mean EF 32 ± 6%. The average age of the patient when started on carvedilol was 69 ± 7
years. Only 7 patients were changed to metoprolol succinate because of adverse side effects. After up-titration of carvedilol, the average resting
heart rate was 61 ± 8 beats per minute. Two hundred and forty patients with HFrEF on carvedilol for greater than 5 years had a significant mean
increase in EF of 5.5 ± 8% (p < 0.05). Two hundred of the patients with HFrEF also had or developed type 2 diabetes and chronic kidney disease
during followup. Thirty-one percent of these patients with type 2 diabetes and chronic kidney disease lived longer than 10 years. Carvedilol
remains a well-tolerated beta-blocker which demonstrates long-term benefits in a real-world setting.